| View printer-friendly version |
Charles River Announces Third-Quarter 2008 Results
WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 5, 2008--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter and first nine months of 2008. For the quarter, net sales increased 9.0% to $342.2 million from $314.0 million in the third quarter of 2007. The Research Models and Services (RMS) segment reported very strong sales growth, partially offset by slower growth in the Preclinical Services (PCS) segment. Foreign exchange contributed 1.5% to the net sales growth.
On a GAAP basis, net income for the third quarter of 2008 was $44.7 million, or $0.63 per diluted share, compared to $42.8 million, or $0.62 per diluted share, for the third quarter of 2007.
On a non-GAAP basis, net income was $53.9 million for the third quarter of 2008, compared to $47.3 million for the same period in 2007, an increase of 13.9%. Third-quarter diluted earnings per share on a non-GAAP basis were $0.76, an increase of 10.1% compared to $0.69 per share in the third quarter of 2007. Non-GAAP earnings per share in the third quarter of 2008 excluded $7.6 million of amortization of intangible assets related to acquisitions; a net charge of $0.7 million related to the Company's dispositions of its legacy preclinical facility in Worcester, Massachusetts, and its Vaccine business in Mexico; expenses of $1.1 million for costs associated with evaluation of bolt-on acquisitions we decided to forego; and a charge of $2.9 million resulting from a deferred tax revaluation related to the Company's convertible debt. For the third quarter of 2007, non-GAAP earnings per share excluded $8.4 million of amortization of intangible assets and stock-based compensation related to acquisitions and a charge of $0.8 million related to pre-acquisition Inveresk stock compensation taxes, partially offset by a $2.0 million gain on the sale of real estate in Scotland and a benefit of $0.9 million resulting from a deferred tax revaluation.
James C. Foster, Chairman, President and Chief Executive Officer, said, "Demand for our portfolio of RMS products remained strong in the third quarter, while demand for PCS services softened. Our clients are continuing to invest in drug discovery and development, but they are facing a range of unprecedented challenges from drugs losing patent protection to the availability of funding for small biotech companies. To address these challenges, our clients are restructuring their businesses, reprioritizing their drug development pipelines and shifting focus to drugs in late-stage development. These actions are leading to significant and accelerating study slippage and delays, pushing work from 2008 into 2009. They are continuing to outsource, but due to heightened cost controls and year-end budget constraints, are spending in a more measured way. We expect these conditions and headwinds from foreign exchange to continue. As a result, we now anticipate our overall 2008 sales and earnings will be lower than our previous forecast."
Mr. Foster continued, "We believe that these market conditions are temporary, and will improve as pharmaceutical and biotechnology companies refocus on the drugs in early development. In the meantime, we are aggressively managing expenses and capital spending, while maintaining an intense focus on supporting our clients with our unique portfolio of products and services which spans the development pipeline from early discovery through proof of concept. Our balance sheet is strong, with $213 million of cash on hand and a favorable debt to equity ratio. Despite this period of softer demand, we are confident that we will maintain our position as a premier provider of essential products and services to the drug development industry."
Research Models and Services (RMS)
Sales for the RMS segment were $165.7 million in the third quarter of 2008, an increase of 14.1% from $145.2 million in the third quarter of 2007. Sales growth was driven by strong global demand from pharmaceutical and biotechnology companies for research models and services, as well as In Vitro Detection products.
In the third quarter of 2008, the RMS segment's GAAP operating margin was 30.6% compared to 31.4% in the third quarter of 2007. The lower margin reflected a greater proportion of services in the sales mix, as well as higher operating costs, particularly in North America. On a non-GAAP basis, which excluded charges of $0.6 million for acquisition-related amortization and $0.3 million related to the disposition of our Vaccine business in Mexico, the operating margin was 31.1% compared to 31.6% for the same period in the prior year. Non-GAAP results in the third quarter of 2007 excluded $0.4 million of amortization related to acquisitions.
Preclinical Services (PCS)
Third-quarter 2008 net sales for the PCS segment were $176.6 million, an increase of 4.6% from $168.8 million in the third quarter of 2007. Growth was driven by expanded capacity in Nevada, which provides significant expertise in large-model safety testing, as well as certain specialty toxicology areas. The PCS sales growth was partially offset by study slippage and delays as a result of pharmaceutical and biotechnology companies' restructuring and pipeline reprioritization and negative foreign currency translation.
The third-quarter GAAP operating margin was 17.2% compared to 17.8% in the third quarter of 2007, due primarily to slower sales growth partially offset by expense management. The segment's profits were also affected, as expected, by the additional costs associated with the transition to the new preclinical facility in Nevada. On a non-GAAP basis, which excluded $7.0 million of acquisition-related amortization and a charge of $0.4 million associated with the Company's disposition of its Worcester, Massachusetts facility, the operating margin declined to 21.4% from 21.8% in the third quarter of 2007. The Company divested the Worcester facility in the third quarter of 2008.
Nine-Month Results
For the first nine months of 2008, net sales increased by 13.1% to $1.03 billion, from $912.6 million in the same period in 2007. Foreign exchange contributed approximately 3.2% to the sales growth rate.
On a GAAP basis, net income was $140.0 million, or $1.98 per diluted share, for the first nine months of 2008, compared to $117.5 million, or $1.72 per diluted share, for the same period in 2007.
On a non-GAAP basis, net income for the first nine months of 2008 was $160.1 million, or $2.26 per diluted share, compared to $134.3 million, or $1.97 per diluted share, for the same period in 2007. For the first nine months of 2008, non-GAAP net income excluded $22.8 million of acquisition-related amortization, a charge of $4.2 million primarily related to the Company's disposition of its Worcester, Massachusetts facility, expenses of $1.1 million for costs associated with evaluation of bolt-on acquisitions we decided to forego, a charge of $2.9 million resulting from a deferred tax revaluation related to the Company's convertible debt, and a gain of $3.3 million as a result of the curtailment of the Company's U.S. defined benefit pension plan. Non-GAAP net income for the same period in 2007 excluded $24.5 million of amortization and stock-based compensation costs associated with acquisitions, a charge of $1.7 million related to the decision to accelerate the exit of the Worcester facility, and a charge of $0.8 million related to pre-acquisition Inveresk stock compensation taxes. Non-GAAP results also excluded a $2.0 million gain on the sale of real estate in Scotland and a benefit of $0.9 million resulting from a deferred tax revaluation.
Research Models and Services (RMS)
For the first nine months of 2008, RMS net sales were $507.1 million, an increase of 17.4% from net sales of $432.1 million in the same period in 2007. The RMS segment's GAAP operating margin was 31.3% in the first nine months of 2008, compared to 31.9% for the year-ago period. On a non-GAAP basis, the operating margin was 31.8% compared to 32.2% in the first nine months of 2007. The lower margins were the result of a greater proportion of services in the sales mix.
Preclinical Services (PCS)
For the first nine months of 2008, PCS net sales were $524.9 million, an increase of 9.2% over net sales of $480.5 million in the same period in 2007. On a GAAP basis, the PCS segment operating margin was 15.7% in the first nine months of 2008, compared to 16.8% in the year-ago period. On a non-GAAP basis, the operating margin was 20.3% in the first nine months of 2008, compared to 21.8% for the same period in 2007. The lower margins were the result of slower sales growth, additional costs associated with the transition to the new preclinical facility in Nevada and start-up costs in China.
2008 Guidance
Based primarily on its expectation that the market for outsourced preclinical services will continue to experience more measured spending by pharmaceutical and biotechnology clients as a result of restructuring and pipeline reprioritization, budget constraints and reduced funding for small biotechnology companies, the Company is reducing its 2008 sales and earnings per share guidance. Sales growth is also expected to be negatively affected by foreign exchange in the fourth quarter of 2008, due to the continued strengthening of the U.S. dollar. The revised forward-looking guidance, which includes the acquisitions of NewLab BioQuality AG and MIR Preclinical Services, is based on current foreign exchange rates.
2008 GUIDANCE REVISED PRIOR
----------------------------------------------------------------------
Net sales growth 9% - 10% 12% - 14%
GAAP EPS estimate $2.48 - $2.52 $2.59 - $2.65
Amortization of intangible assets $0.30 $0.30
Revaluation of deferred tax asset,
impairment and other charges(1) $0.08 $0.07 - $0.08
Gain on curtailment of U.S. defined
benefit pension plan ($0.03) ($0.03)
---------------------------
Non-GAAP EPS estimate $2.83 - $2.87 $2.94 - $3.00
----------------------------------------------------------------------
Footnote 1: The items excluded from non-GAAP earnings per share include: $0.03 related primarily to the Company's disposition of its legacy preclinical facility in Worcester, Massachusetts, $0.01 for expenses associated with bolt-on acquisitions we decided to forego, and $0.04 resulting from a deferred tax revaluation related to the Company's convertible debt.
Webcast
Charles River Laboratories has scheduled a live webcast on Thursday, November 6, at 8:30 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of non-GAAP financial measures to comparable GAAP financial measures on the website.
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share from continuing operations, which exclude amortization of intangible assets and other charges related to our acquisitions, charges related to the dispositions of our legacy preclinical facility in Worcester, Massachusetts, and our Vaccine business in Mexico, expenses associated with evaluating bolt-on acquisitions we decided to forego, the impact of the revaluation of a deferred tax asset related to our convertible debt, and gains attributable to the curtailment of our U.S. pension plan. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not prepared in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions (and in certain cases, the evaluation of such acquisitions, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities, such as business acquisitions, happen infrequently and the underlying costs associated with such activities do not recur on a regular basis. Non-GAAP results also allow investors to compare the Company's operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in the text of this press release, and can also be found on the Company's website at ir.criver.com.
Caution Concerning Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding our projected 2008 sales and earnings; the future demand for drug discovery and development products and services, including the outsourcing of these services and present spending trends by our customers; the impact of specific actions intended to improve overall operating efficiencies and profitability; the timing of the opening of new and expanded facilities by us and our competitors; our future stock purchase activities; future cost reduction activities by our customers; and Charles River's future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to sales growth and foreign exchange impact. In addition, these statements include the expected impact on our revenues and earnings from the acquisitions of NewLab BioQuality AG and MIR Preclinical Services, the availability of funding for our customers and the impact of economic and market conditions on them generally, and the anticipated strength of our balance sheet, our actions designed to manage expenses and capital spending, and the ability of the Company to withstand the current market conditions. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the ability to successfully integrate the acquisitions of NewLab and MIR; a decrease in research and development spending, a decrease in the level of outsourced services, or other cost reduction actions by our customers; the ability to convert backlog to sales; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 20, 2008, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.
About Charles River
Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our more than 9,000 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(dollars in thousands, except for per share data)
Three Months Ended Nine Months Ended
------------------------- -------------------------
September September September September
27, 29, 27, 29,
2008 2007 2008 2007
Total net sales $ 342,227 $ 313,964 $ 1,032,046 $ 912,598
Cost of products
sold and services
provided 211,957 190,065 633,412 552,170
------------ ------------ ------------ ------------
Gross margin 130,270 123,899 398,634 360,428
Selling, general
and
administrative 54,450 51,847 174,820 160,956
Amortization of
intangibles 7,609 8,421 22,780 24,415
------------ ------------ ------------ ------------
Operating income 68,211 63,631 201,034 175,057
Interest income
(expense) (1,290) (2,328) (3,163) (6,982)
Other income
(expense) (1,397) (861) (2,501) (1,781)
------------ ------------ ------------ ------------
Income before
income taxes and
minority
interests 65,524 60,442 195,370 166,294
Provision for
income taxes 20,819 16,808 55,665 47,219
------------ ------------ ------------ ------------
Income before
minority
interests 44,705 43,634 139,705 119,075
Minority interests (5) (98) 336 (471)
------------ ------------ ------------ ------------
Income from
continuing
operations 44,700 43,536 140,041 118,604
Loss from
discontinued
businesses, net
of tax - (759) - (1,108)
------------ ------------ ------------ ------------
Net income (loss) $ 44,700 $ 42,777 $ 140,041 $ 117,496
============ ============ ============ ============
Earnings (loss)
per common share
Basic:
Continuing
operations $ 0.67 $ 0.65 $ 2.08 $ 1.78
Discontinued
operations $ - $ (0.01) $ - $ (0.02)
Net income $ 0.67 $ 0.64 $ 2.08 $ 1.76
Diluted:
Continuing
operations $ 0.63 $ 0.63 $ 1.98 $ 1.74
Discontinued
operations $ - $ (0.01) $ - $ (0.02)
Net income $ 0.63 $ 0.62 $ 1.98 $ 1.72
Weighted average
number of common
shares
outstanding
Basic 67,167,827 67,192,236 67,380,141 66,813,724
Diluted 70,924,697 69,077,747 70,692,234 68,158,843
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(dollars in thousands)
September 27, December 29,
2008 2007
Assets
Current assets
Cash and cash equivalents $ 212,851 $ 225,449
Trade receivables, net 237,268 213,908
Inventories 93,537 88,023
Other current assets 74,594 79,477
Current assets of discontinued
businesses 575 1,007
------------- ------------
Total current assets 618,825 607,864
Property, plant and equipment, net 845,130 748,793
Goodwill, net 1,154,865 1,120,540
Other intangibles, net 152,465 148,905
Deferred tax asset 62,875 89,255
Other assets 58,535 85,993
Long-term assets of discontinued businesses 4,187 4,187
------------- ------------
Total assets $2,896,882 $2,805,537
============= ============
Liabilities and Shareholders' Equity
Current liabilities
Current portion of long-term debt $ 239,030 $ 25,051
Accounts payable 36,367 36,715
Accrued compensation 48,937 53,359
Deferred revenue 85,470 102,021
Accrued liabilities 69,872 61,366
Other current liabilities 32,718 23,268
Current liabilities of discontinued
businesses 116 748
------------- ------------
Total current liabilities 512,510 302,528
Long-term debt 303,681 484,998
Other long-term liabilities 132,617 154,044
------------- ------------
Total liabilities 948,808 941,570
------------- ------------
Minority interests 780 3,500
Total shareholders' equity 1,947,294 1,860,467
------------- ------------
Total liabilities and shareholders' equity $2,896,882 $2,805,537
============= ============
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)
Three Months Ended Nine Months Ended
------------------- ---------------------
September September September September
27, 29, 27, 29,
2008 2007 2008 2007
Research Models and Services
Net sales $165,656 $145,207 $ 507,100 $432,078
Gross margin 70,813 63,408 223,498 190,171
Gross margin as a % of
net sales 42.7% 43.7% 44.1% 44.0%
Operating income 50,673 45,574 158,685 137,863
Operating income as a %
of net sales 30.6% 31.4% 31.3% 31.9%
Depreciation and
amortization 7,043 5,780 20,718 17,012
Capital expenditures 12,572 12,643 46,228 30,415
Preclinical Services
Net sales $176,571 $168,757 $ 524,946 $480,520
Gross margin 59,457 60,491 175,136 170,257
Gross margin as a % of
net sales 33.7% 35.8% 33.4% 35.4%
Operating income 30,390 29,993 82,507 80,863
Operating income as a %
of net sales 17.2% 17.8% 15.7% 16.8%
Depreciation and
amortization 15,894 16,180 47,572 46,093
Capital expenditures 33,577 37,692 103,802 107,256
Unallocated Corporate
Overhead $(12,852) $(11,936) $ (40,158) $(43,669)
Total
Net sales $342,227 $313,964 $1,032,046 $912,598
Gross margin 130,270 123,899 398,634 360,428
Gross margin as a % of
net sales 38.1% 39.5% 38.6% 39.5%
Operating income (loss) 68,211 63,631 201,034 175,057
Operating income as a %
of net sales 19.9% 20.3% 19.5% 19.2%
Depreciation and
amortization 22,937 21,960 68,290 63,105
Capital expenditures 46,149 50,335 150,030 137,671
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)
Three Months Ended Nine Months Ended
------------------- ---------------------
September September September September
27, 29, 27, 29,
2008 2007 2008 2007
Research Models and Services
Net sales $165,656 $145,207 $ 507,100 $432,078
Operating income 50,673 45,574 158,685 137,863
Operating income as a %
of net sales 30.6% 31.4% 31.3% 31.9%
Add back:
Amortization related
to acquisitions 602 380 1,730 1,125
Impairment and other
charges 315 - 949 -
--------- --------- ----------- ---------
Operating income,
excluding specified
charges (Non-GAAP) $ 51,590 $ 45,954 $ 161,364 $138,988
Non-GAAP operating income
as a % of net sales 31.1% 31.6% 31.8% 32.2%
Preclinical Services
Net sales $176,571 $168,757 $ 524,946 $480,520
Operating income 30,390 29,993 82,507 80,863
Operating income as a %
of net sales 17.2% 17.8% 15.7% 16.8%
Add back:
Amortization related
to acquisitions 7,007 8,041 21,050 23,290
Impairment and other
charges 360 - 3,233 1,682
Gain on sale of UK
real estate - (2,047) - (2,047)
Pre-acquisition
Inveresk stock
compensation taxes - 845 - 845
--------- --------- ----------- ---------
Operating income,
excluding specified
charges (Non-GAAP) $ 37,757 $ 36,832 $ 106,790 $104,633
Non-GAAP operating income
as a % of net sales 21.4% 21.8% 20.3% 21.8%
Unallocated Corporate
Overhead $(12,852) $(11,936) $ (40,158) $(43,669)
Add back:
Stock-based
compensation related
to Inveresk
acquisition - 6 - 94
Expensed deal costs 1,125 - 1,125 -
Pension curtailment - - (3,276) -
--------- --------- ----------- ---------
Unallocated corporate
overhead, excluding
specified charges (Non-
GAAP) $(11,727) $(11,930) $ (42,309) $(43,575)
Total
Net sales $342,227 $313,964 $1,032,046 $912,598
Operating income 68,211 63,631 201,034 175,057
Operating income as a %
of net sales 19.9% 20.3% 19.5% 19.2%
Add back:
Amortization related
to acquisition 7,609 8,421 22,780 24,415
Stock-based
compensation related
to Inveresk
acquisition - 6 - 94
Impairment and other
charges 675 - 4,182 1,682
Expensed deal costs 1,125 - 1,125 -
Pension curtailment - - (3,276) -
Gain on sale of UK
real estate - (2,047) - (2,047)
Pre-acquisition
Inveresk stock
compensation taxes - 845 - 845
--------- --------- ----------- ---------
Operating income,
excluding specified
charges (Non-GAAP) $ 77,620 $ 70,856 $ 225,845 $200,046
Non-GAAP operating income
as a % of net sales 22.7% 22.6% 21.9% 21.9%
Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of one-time charges, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS
(dollars in thousands, except for per share data)
Three Months Ended Nine Months Ended
------------------------- -------------------------
September September September September
27, 29, 27, 29,
2008 2007 2008 2007
Net income (loss) $ 44,700 $ 42,777 $ 140,041 $ 117,496
Less: Discontinued
operations - 759 - 1,108
------------ ------------ ------------ ------------
Net income from
continuing
operations 44,700 43,536 140,041 118,604
Add back:
Amortization
related to
acquisitions 7,609 8,421 22,780 24,415
Stock-based
compensation
related to
Inveresk
acquisition - 6 - 94
Impairment and
other charges 675 - 4,182 1,682
Expensed deal
costs 1,125 - 1,125 -
Pension
curtailment - - (3,276) -
Gain on sale of
UK real estate - (2,047) - (2,047)
Pre-acquisition
Inveresk stock
compensation
taxes - 845 - 845
Deferred tax
revaluation 2,921 (907) 2,921 (907)
Tax effect (3,102) (2,517) (7,669) (8,362)
------------ ------------ ------------ ------------
Net income from
continuing
operations,
excluding
specified charges
(Non-GAAP) $ 53,928 $ 47,337 $ 160,104 $ 134,324
============ ============ ============ ============
Weighted average
shares
outstanding -
Basic 67,167,827 67,192,236 67,380,141 66,813,724
Effect of dilutive
securities:
2.25% senior
convertible
debentures 1,752,046 526,591 1,547,131 85,190
Stock options
and
contingently
issued
restricted
stock 1,385,703 1,226,004 1,359,051 1,126,481
Warrants 619,121 132,916 405,911 133,448
------------ ------------ ------------ ------------
Weighted average
shares
outstanding -
Diluted 70,924,697 69,077,747 70,692,234 68,158,843
============ ============ ============ ============
Basic earnings
(loss) per share $ 0.67 $ 0.64 $ 2.08 $ 1.76
Diluted earnings
(loss) per share $ 0.63 $ 0.62 $ 1.98 $ 1.72
Basic earnings per
share, excluding
specified charges
(Non-GAAP) $ 0.80 $ 0.70 $ 2.38 $ 2.01
Diluted earnings
per share,
excluding
specified charges
(Non-GAAP) $ 0.76 $ 0.69 $ 2.26 $ 1.97
Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of one-time charges, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations.
CONTACT: Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
or
Media Contact:
Amy Cianciaruso, 781-222-6168
Associate Director, Public Relations
SOURCE: Charles River Laboratories International, Inc.